Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Argent Biopharma ( (AU:RGT) ) has provided an update.
Argent BioPharma has initiated the supply of EU-GMP cannabinoid-based active pharmaceutical ingredients (API) for epilepsy treatment at the University Medical Centre Ljubljana, Slovenia’s largest hospital. This follows a successful pilot program and marks a significant milestone in the company’s operations, enhancing its market position in Europe. The collaboration with Slovenian health authorities and the hospital demonstrates Argent’s leadership in cannabinoid regulations and expands its commercial opportunities within the EU. The initiative strengthens Argent’s Epilepsy Program Platform (EPP) and supports future EU and U.S. expansion, providing evidence-based treatment options for complex epilepsy cases.
More about Argent Biopharma
Argent BioPharma Ltd. (ASX: RGT) is a clinical-stage biopharmaceutical company specializing in nano-engineered therapeutics aimed at balancing the nervous and immune systems. The company’s primary products, CannEpil® and CimetrA®, focus on treating drug-resistant epilepsy and cytokine-driven inflammatory disorders. Argent BioPharma’s proprietary delivery technologies enhance drug penetration across critical barriers, supporting unique efficacy and protection. The company emphasizes urgent unmet needs in CNS and systemic inflammation, excluding oncology, and operates with integrated EU-GMP manufacturing and a Neuro-Immune Modulatory platform.
Average Trading Volume: 39,216
Technical Sentiment Signal: Sell
Current Market Cap: A$4.94M
For a thorough assessment of RGT stock, go to TipRanks’ Stock Analysis page.